Publication of ChondroCelect pivotal trial results honoured with prestigious award
Leuven (BELGIUM) - July 13, 2009 - TiGenix (NYSE EURONEXT BRUSSELS: TIG)announces that the American Journal of Sports Medicine publication on the positive structural results of the ChondroCelect pivotal trial was awarded with the Hughston Award.
Every year, the American Orthopaedic Society for Sports Medicine (AOSSM) recognises the individuals who have made significant contributions to orthopaedic sports medicine. The Hughston Award is given for the most outstanding paper that appeared in The American Journal of Sports Medicine (AJSM) the year prior to the award. This award was established in honour of Jack C. Hughston, MD, the founder of AJSM. Dr. Daniël Saris, orthopaedic surgeon at the UMC Utrecht and one of the first authors of the publication, received the
Award last Saturday at the AOSSM 2009 Annual Meeting in Keystone, Colorado, US.
The publication entitled: 'Characterized Chondrocyte Implantation results in better structural repair when treating symptomatic cartilage defects of the knee in a randomized controlled trial versus microfracture' by D. Saris, J. Vanlauwe et al. appeared in the February 2008 issue of the ASJM (Vol. 36, No.2, pp. 235-246). The manuscript describes the superior
structural outcome one year after ChondroCelect implantation compared to microfracture for the treatment of symptomatic cartilage defects in the knee.
On June 26, 2009, ChondroCelect was the first cell therapy product to receive a positive opinion from the Committee for Advanced Therapies (CAT) and the Committee for Medicinal Products for Human Use (CHMP) on the European Marketing Authorisation application (MAA) under the new regulation on advanced-therapy medicinal products.
'This prestigious award means a lot to me and to the entire study team and confirms that we are on the right track with regenerative medicine at our respective institutes. It is the
recognition of years of solid clinical research and will significantly contribute to the field of regenerative medicine. The recent positive CHMP-feedback in Europe can only confirm
this.' said Dr. Daniël Saris.
For more information, please contact:
Gil Beyen
CEO
+32 (0)16 39 60 60
+32 (0)16 39 60 98
gil.beyen@tigenix.com
Kris Motmans
representative of Comfi
Corporate Communications
kris.motmans@tigenix.com
Every year, the American Orthopaedic Society for Sports Medicine (AOSSM) recognises the individuals who have made significant contributions to orthopaedic sports medicine. The Hughston Award is given for the most outstanding paper that appeared in The American Journal of Sports Medicine (AJSM) the year prior to the award. This award was established in honour of Jack C. Hughston, MD, the founder of AJSM. Dr. Daniël Saris, orthopaedic surgeon at the UMC Utrecht and one of the first authors of the publication, received the
Award last Saturday at the AOSSM 2009 Annual Meeting in Keystone, Colorado, US.
The publication entitled: 'Characterized Chondrocyte Implantation results in better structural repair when treating symptomatic cartilage defects of the knee in a randomized controlled trial versus microfracture' by D. Saris, J. Vanlauwe et al. appeared in the February 2008 issue of the ASJM (Vol. 36, No.2, pp. 235-246). The manuscript describes the superior
structural outcome one year after ChondroCelect implantation compared to microfracture for the treatment of symptomatic cartilage defects in the knee.
On June 26, 2009, ChondroCelect was the first cell therapy product to receive a positive opinion from the Committee for Advanced Therapies (CAT) and the Committee for Medicinal Products for Human Use (CHMP) on the European Marketing Authorisation application (MAA) under the new regulation on advanced-therapy medicinal products.
'This prestigious award means a lot to me and to the entire study team and confirms that we are on the right track with regenerative medicine at our respective institutes. It is the
recognition of years of solid clinical research and will significantly contribute to the field of regenerative medicine. The recent positive CHMP-feedback in Europe can only confirm
this.' said Dr. Daniël Saris.
For more information, please contact:
Gil Beyen
CEO
+32 (0)16 39 60 60
+32 (0)16 39 60 98
gil.beyen@tigenix.com
Kris Motmans
representative of Comfi
Corporate Communications
kris.motmans@tigenix.com
Subscribe to our newsletter
Stay tuned and get our news in your inbox: subscribe here.
Keep me informed
